$145-200k
+ Equity
Obesity and metabolic health treatment
Open for applications
Obesity and metabolic health treatment
201-500 employees
Open for applications
$145-200k
+ Equity
201-500 employees
To change the way the world treats weight.
Jump to section
To change the way the world treats weight.
Few candidates hear
back within 2 weeks
-23% employee growth in 12 months
Obesity affects four in ten Americans, but treatment has long been overlooked, often categorized as a lifestyle problem rather than a healthcare issue. Calibrate is changing that by offering a combination of cutting-edge medication and physiological training to help people make lasting changes to their weight.
The medications used by Calibrate, including GLP-1 drugs, have shown strong results in clinical trials. When combined with sustainable lifestyle changes, its program helps patients achieve lasting weight loss. However, while these medications show promise, long-term safety and effectiveness still require further study, especially since continued use is necessary to prevent weight regain.
Despite these concerns, Calibrate's approach has helped over 20,000 people, and many have sustained health improvements well beyond the first year. It has faced some challenges, including negative press and a round of layoffs, but with funding and positive attention around next-gen weight loss drugs, the company continues to be a leader in the field.
Steph
Company Specialist at Welcome to the Jungle
Nov 2023
$29m
GROWTH EQUITY VC
Aug 2021
$100m
SERIES B
This company has top investors
Rob MacNaughton
(CEO)Joined Calibrate in January 2024 at CEO. Prior to that, they were the CEO of Curve Health. They also served as the CEO of NurseGrid and as a Senior Vice President and CPO at Cambia Health Solutions.
Software Engineering
People, HR, Recruitment
Sales & Account Management